Tanshinone IIA prevents rat basilar artery smooth muscle cells proliferation by inactivation of PDK1 during the development of hypertension

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 6, 2015, Pages 563-571

  Yu, Zhi Liang ^a   Wang, Jie Ning ^a   Wu, Xiao Hua ^a   Xie, Hui Jun ^b   Han, Ying ^a   Guan, Yang Tai ^b   Qin, Yong ^a   Jiang, Jian Ming ^b  

^a SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

basilar vascular smooth muscle cells; endothelin 1; hypertension; PDK1; proliferation; tanshinone IIA

Indexed keywords

CYCLIN D1; ENDOTHELIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P27; TANSHINONE IIA; BENZOFURAN DERIVATIVE; CCND1 PROTEIN, RAT; CDKN1B PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; TASHINONE IIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERY DIAMETER; ARTERY MUSCLE; ARTICLE; BASILAR ARTERY; BLOOD PRESSURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HYPERTENSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CELL CYCLE; CYTOLOGY; DRUG EFFECTS; GENETICS; PATHOLOGY; PHOSPHORYLATION; RENOVASCULAR HYPERTENSION; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BASILAR ARTERY; BENZOFURANS; BLOOD PRESSURE; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIN-1; HYPERTENSION; HYPERTENSION, RENOVASCULAR; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84943595559     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415574743     Document Type: Article

References (29)

1. Lemarié CA, Tharaux PL, Lehoux S,. Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol. 2010; 48 (3): 433-439.
2. Nasser SA, El-Mas MM,. Endothelin ETA receptor antagonism in cardiovascular disease. Eur J Pharmacol. 2014; 737: 210-213.
3. Wang W, Zheng LL, Wang F, et al. Tanshinone IIA attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide. J Ethnopharmacol. 2010; 134 (1): 147-155.
4. Shang YH, Tian JF, Hou M, Xu XY,. Progress on the protective effect of compounds from natural medicines on cerebral ischemia. Chin J Nat Med. 2013; 11 (6): 588-595.
5. Wang J, Dong MQ, Liu ML, et al. Tanshinone IIA modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca2+ influx and release in normal and hypoxic pulmonary hypertension rats. Eur J Pharmacol. 2010; 640 (1-3): 129-138.
6. Maione F, De Feo V, Caiazzo E, De Martino L, Cicala C, Mascolo N,. Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway. J Ethnopharmacol. 2014; 155 (2): 1236-1242.
7. Stumpf C, Fan Q, Hintermann C, et al. Anti-inflammatory effects of danshen on human vascular endothelial cells in culture. Am J Chin Med. 2013; 41 (5): 1065-1077.
8. Jia LQ, Yang GL, Ren L, et al. Tanshinone IIA reduces apoptosis induced by hydrogen peroxide in the human endothelium-derived EA.hy926 cells. J Ethnopharmacol. 2012; 143 (1): 100-108.
9. Jin HJ, Li CG,. Tanshinone IIA and Cryptotanshinone prevent mitochondrial dysfunction in hypoxia-induced H9c2 cells: association to mitochondrial ROS, intracellular nitric oxide, and calcium levels. Evid Based Complement Alternat Med. 2013; 2013: 610694.
10. Kim DD, Sánchez FA, Durán RG, Kanetaka T, Durán WN,. Endothelial nitric oxide synthase is a molecular vascular target for the Chinese herb Danshen in hypertension. Am J Physiol Heart Circ Physiol. 2007; 292 (5): H2131-H2137.
11. Wang P, Wu X, Bao Y, et al. Tanshinone IIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats. Pharmazie. 2011; 66 (7): 517-524.
12. Fan Z, Li C, Qin C, et al. Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. DNA Cell Biol. 2014; 33 (1): 12-19.
13. Hofler A, Nichols T, Grant S, et al. Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Anal Biochem. 2011; 414 (2): 179-186.
14. Andjelković M, Alessi DR, Meier R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997; 272 (50): 31515-31524.
15. Garat CV, Crossno JT Jr, Sullivan TM, Reusch JE, Klemm DJ,. Inhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. J Cardiovasc Pharmacol. 2013; 62 (6): 539-548.
16. Zeng J, Zhang Y, Mo J, Su Z, et al. Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats. Stroke. 1998; 29 (8): 1708-1713.
17. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13 (2): 189-197.
18. Wang M, Yang H, Zheng LY, et al. Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation. Circulation. 2012; 125 (5): 697-707.
19. Ma MM, Li SY, Wang M, Guan YY,. Simvastatin attenuated cerebrovascular cell proliferation in the development of hypertension through Rho/Rho-kinase pathway. J Cardiovasc Pharmacol. 2012; 59 (6): 576-582.
20. Schiffrin EL,. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001; 14 (6 pt 2): 83S-89S.
21. Ward MR, Pasterkamp G, Yeung AC, Borst C,. Arterial remodeling. Mechanisms and clinical implications. Circulation. 2000; 102 (10): 1186-1191.
22. Zhou L, Zuo Z, Chow MS,. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005; 45 (12): 1345-1359.
23. Cui L, Wu T, Liu YY, et al. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol Sin. 2004; 25 (5): 678-684.
24. Wang AM, Sha SH, Lesniak W, et al. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother. 2003; 47 (6): 1836-1841.
25. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD,. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17: 615-675.
26. Wu MH, Lo JF, Kuo CH, et al. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. J Cell Physiol. 2012; 227 (8): 3016-3026.
27. Shen X, Xi G, Radhakrishnan Y, et al. PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-i-stimulated AKT activation and vascular smooth muscle cell survival. J Biol Chem. 2010; 285 (38): 29416-29424.
28. Alcántara-Hernández R, Hernández-Méndez A, Adolfo García-Sáinz J,. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases. Eur J Pharmacol. 2004; 740: 88-96.
29. King CC, Newton AC,. The adaptor protein Grb14 regulates the localization of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2004; 279 (36): 37518-37527.